GALNT6 promotes bladder cancer malignancy and immune escape by epithelial-mesenchymal transition and CD8⁺ T cells.

ABSTRACT: Bladder cancer (BC) ranks as the sixth cancer in males and the ninth most common cancer worldwide. Conventional treatment modalities, including surgery, radiation, chemotherapy, and immunotherapy, have limited efficacy in certain advanced instances. The involvement of GALNT6-mediated aberrant O-glycosylation modification in several malignancies and immune evasion is a subject of speculation. However, its significance in BC has not been investigated. Through the integration of bioinformatics analysis and laboratory experimentation, we have successfully clarified the role of GALNT6 in BC. Our investigation revealed that GALNT6 has significant expression in BC, and its high expression level correlates with advanced stage and high grade, leading to poor overall survival. Moreover, both in vitr

SUBMITTER: Sun X 

PROVIDER: S-EPMC11382498 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature